Fourth Invivo Therapeutics INSPIRE study patient improves AIS grade

126

InVivo Therapeutics has announced that the sixth-implanted patient in the INSPIRE study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold for Safety and Neurologic Recovery in Subjects with Complete Thoracic American Spinal Injury Association Impairment Scale (AIS) A Spinal Cord Injury) has improved from a complete AIS A spinal cord injury to an incomplete AIS B spinal cord injury.

This is the fourth out of the first six patients (67%) with at least two months of follow up data to have had an AIS grade improvement.

The Objective Performance Criterion (OPC), a measure of study success for the INSPIRE study, is defined as 25% or more of the patients having improved by at least one AIS grade by six months post-implantation. Several large natural history databases indicate that fewer than 16% of patients with complete thoracic injuries have an AIS grade improvement by six months post-injury.

“We are encouraged by the progress the patient has made in the first two months after injury. It is still early in the patient’s recovery period, and we look forward to monitoring this patient for signs of further neurological recovery,” said Wilson Ray. Ray performed the implantation at the Barnes-Jewish Hospital at Washington University Medical Center (St Louis, USA).

All patients enrolled in the INSPIRE study have complete (AIS A) spinal cord injuries at the time of enrollment.